Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11629164 Gemcitabine prodrugs

Patent 11629164 was granted and assigned to NuCana on April, 2023 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Valentina Ferrari0

Hugh Griffith0

Magdalena Slusarczyk0

Michaela Serpi0

Christopher McGuigan0

Date of Patent

April 18, 2023

0

Patent Application Number

168655270

Date Filed

May 4, 2020

0

Patent Citations

US Patent 10786523 Formulation comprising a gemcitabine-prodrug

US Patent 10005810 Process for preparing nucleoside prodrugs

0

US Patent 10117888 Formulation comprising a gemcitabine-prodrug

0

US Patent 10660912 Combination therapy for cancer

0

US Patent 10662213 Gemcitabine prodrugs

0

US Patent 11040051 Formulation comprising a gemcitabine-prodrug

0

Patent Primary Examiner

Traviss C Mcintosh, III

0

This invention relates to a prodrug of the monophosphate nucleotide of the well-known oncology drug gemcitabine. Specifically, it relates to gemcitabine-[phenyl-benzoxy-

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11629164 Gemcitabine prodrugs

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool